Imatinib should continue to be the front-line therapy for patients who have newly diagnosed chronic myelogenous leukemia accompanied by close monitoring. Patients should switch to a second-generation tyrosine kinase inhibitor at the earliest sign of resistance or suboptimal response to imatinib.
|Original language||English (US)|
|Number of pages||4|
|State||Published - Jan 15 2011|
ASJC Scopus subject areas
- Cancer Research